Neuraxis, INC
Neuraxis CRO Thomas Carrico bought 328 shares at $4.84 each, totaling $1,587. He now holds 199,673 shares. NRXS shares are up 40% since his purchase and 116% over the past year. Neuraxis reported Q2 2026 revenue growth of 116% to $1.928 million but a wider loss of $0.19 per share. The company's gross margins improved.
Neuraxis CFO Timothy Henrichs bought 1,937 shares of Neuraxis (NRXS) stock at $4.84 per share, totaling $9,375. The company reported a 116% revenue increase to $1.928M in Q2 2026, but a wider loss of $0.19 per share. NRXS shares are up 40% since the purchase, with a 116% return over the past year.
Carrico Brian Allen (Chief Executive Officer) purchased 268 shares of Neuraxis, INC (NRXS) at $4.84 on 2026-10-08.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning NRXS (Neuraxis, INC). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent NRXS coverage spans insider activity, financial news and market movers.
In the last 30 days, NRXS insiders filed 3 SEC Form 4 transactions — 3 purchases ($12K) and no sales. The most active reporter was Henrichs Timothy Robert, Chief Financial Officer, with 1 filing.
Insider buying may signal confidence and could support short-term price upside.
Small insider purchase may create modest bullish pressure.
The small insider purchase may signal confidence but is unlikely to move the stock materially.
Small insider purchase likely signals confidence but size is negligible for price.
The insider purchase is modest in size but may signal confidence from the CFO, providing slight upward pressure on the stock.
AlphAI scores every news story that mentions NRXS with an AI model for sentiment and relevance, and aggregates insider trades from Neuraxis, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Neuraxis CRO Thomas Carrico bought 328 shares at $4.84 each, totaling $1,587. He now holds 199,673 shares. NRXS shares are up 40% since his purchase and 116% over the past year. Neuraxis reported Q2 2026 revenue growth of 116% to $1.928 million but a wider loss of $0.19 per share. The company's gross margins improved.
1 min readNeuraxis CFO Timothy Henrichs bought 1,937 shares of Neuraxis (NRXS) stock at $4.84 per share, totaling $9,375. The company reported a 116% revenue increase to $1.928M in Q2 2026, but a wider loss of $0.19 per share. NRXS shares are up 40% since the purchase, with a 116% return over the past year.
2 min readCarrico Brian Allen (Chief Executive Officer) purchased 268 shares of Neuraxis, INC (NRXS) at $4.84 on 2026-10-08.
1 min readCarrico Thomas Joeseph (CRO, CCO, CPO) purchased 328 shares of Neuraxis, INC (NRXS) at $4.84 on 2026-10-08.
1 min readHenrichs Timothy Robert (Chief Financial Officer) purchased 1,937 shares of Neuraxis, INC (NRXS) at $4.84 on 2026-10-08.
1 min readDataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
3 min readNeurAxis (NRXS) shares rose 25% to $7.15 after announcing new medical coverage from a major insurer for its Percutaneous Electrical Nerve Field Stimulation, affecting 18 million members. The stock opened at $6.14 and peaked at $7.30.
1 min readNeurAxis (NRXS) announced that a major national insurer expanded coverage for its PENFS therapy, adding 18 million members, bringing total coverage to 120 million. The company's IB-Stim device is FDA-cleared for pediatric abdominal pain. CEO Brian Carrico highlighted growth acceleration and plans to pursue additional insurers. NRXS stock is up 21.77% to $6.94.
2 min readNeurAxis (NRXS) announced a major national health insurer will cover its IB-Stim device for treating abdominal pain in patients aged 8+. The coverage applies to 18M members across multiple states. The FDA-cleared device is a non-invasive neuromodulation technology. NeurAxis aims to secure coverage from more insurers and is conducting additional clinical trials. The company did not disclose the insurer's name or provide financial projections.
2 min readEastman Kodak (KODK) reported 18% YOY revenue growth to $311M, with print and advanced materials segments up 10% and 40% respectively. Gross margin improved 700 bps to 26%, and operational EBITDA grew to $36M. The company is exploring new markets like EV batteries and pharma reagents. NeurAxis (NRXS) also shows potential with high gross margins and product traction.
3 min read
